CCO Oncology Podcast

189 Episodo

1. Rationale for NTRK Testing in Patients With Cancer

   Publicado: 8/10/2021
2. Expert Answers to HCP Questions on Androgen Deprivation Therapy for Prostate Cancer

   Publicado: 7/10/2021
3. Expert Insight on Important Clinical Trial Data From ESMO 2021 Informing Treatment for Endometrial and Ovarian Cancer

   Publicado: 29/9/2021
4. Expert Insight on New Evidence Poised to Change the Treatment Landscape in Melanoma

   Publicado: 28/9/2021
5. Expert Insight on Practice Changing From IGCS 2021 Informing Treatment for Endometrial, Ovarian, and Cervical Cancer

   Publicado: 21/9/2021
6. Integrating New Therapies Into the Management of Relapsed/Refractory Myeloma: Experts Address FAQs

   Publicado: 24/8/2021
7. Expert Insights on Optimal Use of CDK4/6 Inhibitors for HR-Positive/HER2-Negative Breast Cancer

   Publicado: 19/8/2021
8. Essential Biomarker Testing in GI Cancers

   Publicado: 18/8/2021
9. CDK4/6 Inhibitors in Early-Stage HR+/HER2- Breast Cancer: Expert Answers to Clinician Questions

   Publicado: 5/8/2021
10. The Latest Advances and Guidance in Nonmetastatic Castration-Resistant Prostate Cancer

    Publicado: 30/7/2021
11. Managing Serious Adverse Events Associated with BTK Inhibitor Treatment

    Publicado: 27/7/2021
12. Strategies for Avoiding Adverse Reactions to BTK Inhibitor Therapy, Part 2: Patient Strategies for Self-Management

    Publicado: 27/7/2021
13. Strategies for Avoiding Adverse Reactions to BTK Inhibitor Therapy, Part 1: Drug–Drug and Drug–Food Interactions

    Publicado: 27/7/2021
14. BTK Inhibitors in CLL and Lymphomas: Overview and Current Indications

    Publicado: 23/7/2021
15. Adverse Events Associated with BTK Inhibitor Treatment

    Publicado: 23/7/2021
16. Radiopharmaceuticals in the Treatment of Metastatic Castration-Resistant Prostate Cancer

    Publicado: 20/7/2021
17. How to Integrate Novel Treatment Classes for R/R Myeloma Into Clinical Practice: Information on BCMA-Targeted Therapies

    Publicado: 19/7/2021
18. Expert Answers to HCP Questions on CAR T-Cell Therapy

    Publicado: 19/7/2021
19. How to Integrate Novel Treatment Classes for R/R Myeloma Into Clinical Practice: Information on Selinexor, Venetoclax, and Melphalan Flufenamide

    Publicado: 16/7/2021
20. Caring for Patients With Newly Diagnosed Multiple Myeloma

    Publicado: 14/7/2021